Low Cost Covid Test Kits from swiss point of care
From only £4.80+VAT per test!
Swiss Point of Care provides accurate yet inexpensive lateral flow rapid test kits for Coronavirus. These kits are approved to 98/79 EC directive and have excellent performance with accuracy of 99.3% and specificity of 99.6% in clinical trials.
As well as being extremely accurate, these tests are the lowest cost option in our range, thanks to the separate bottle of buffer fluid. If you require pre-filled vials, please see our Hughes Healthcare kits.
The nasal swab method used in Swiss Point of Care test kits compares well to the nasopharyngeal test method – where the swab needs to be inserted to the back of the throat.
The nose and throat (nasopharyngeal) tests are not as comfortable as these nasal-only swab test kits, which only needs to be inserted about 2-3cm into each nostril. These test kits are especially suitable for testing children, but adults also find them a more pleasant experience.
The Swiss Point of Care COVID-19 rapid test kit contains everything you will need for a rapid coronavirus test. There are 25 test kits per pack.
Test Kit Component Quantities per pack:
- x 25 Rapid test device.
- x 25 Swab kit.
- x 25 Liquid buffer solution.
- x 25 Pipette.
See a view of the contents of this kit on the right here:
From only £4.80 EXC VAT per test
|Quantity Purchased||Price Per Case of 25|
|1 – 3||£167.25 exc. VAT|
|4 – 9||£160.00 exc. VAT|
|10 – 39||£157.50 exc. VAT|
|40 – 199||£131.25 exc. VAT|
|200 – 399||£126.25 exc. VAT|
|400 +||£120.00 exc. VAT|
Read Our Reviews
About Swiss Point of Care Kits
These kits are easy to use, inexpensive and yield accurate information on whether someone is actively infected with COVID-19 very quickly.
Information and data from the results of these tests can be utilised by the authorities to better understand the variants and distribution of the virus.
Whether you want to quickly test a group or individuals, test kits from this brand are a safe and ideal choice for professional testing.
Please see the instruction sheet within the kit and follow it carefully.
The clinical trials results for this rapid test kit is shown below:
|Sensitivity||97.1%||83.8% – 99.9%|
|Specificity||99.6%||97.7% – 99.9%|
|Accuracy||99.3%||97.5% – 99.9%|
These test kits are manufactured by Acon Labs in China, and registered by MedNet Gmbh in Germany in accordance with the directive 98/79EC of the European Parliament and the Council of the European Union relating to in vitro diagnostic medical devices.
Using This Rapid Test Kit
Please see the instruction sheet within the rapid test kit and follow it carefully as false-negative results are very much to be avoided.
When incorrect results occur it is normally because of reading the lateral flow test too quickly.
You can also view our blog to see a full comparison between 5 major test kit manufacturers.
Need a Complete Rapid Testing Station Package?
Save money with our convenient Covid Testing Station Bundle including PPE, Test Kits, and Social Distancing Screens!
Instructions for Use of Rapid COVID-19 Tests
A nasal swab sample is collected from the person being tested using the sterile swab within your kit.
The swab is then inserted into a bottle that contains 2 ml of buffer solution. The swab containing cell samples should be stirred well and pressed to the bottom of the bottle.
The swab should be stirred well and the test cassette removed from the foil packaging.
3-4 drops of sample are dripped on to the lateral flow device (LFD). The result will be shown in 15 minutes.
Video on how lateral flow testing works:
The Nasal Swab Collection Proceedure:
Please note: these Swiss Point Of Care rapid COVID test kits require a nasal swab only.
Further Information on the low cost Swiss Point Of Care Lateral Flow Rapid Covid Test Kits:
Swiss Point of Care SARS-CoV-2 Antigen Rapid Tests
A rapid test for the qualitative detection of SARS-CoV-2 nucleocapsid antigens in nasal swab specimens.
For professional in vitro diagnostic use only.
The SARS-CoV-2 Antigen Rapid Test is a lateral flow chromatographic immunoassay for the qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 in nasal swab specimens directly from individuals who are suspected of COVID-19 by their healthcare provider within the first seven days of the onset of symptoms. The SARS-CoV-2 Antigen Rapid Test does not differentiate between SARS-CoV and SARS-CoV-2.
Results are for the identification of SARS-CoV-2 nucleocapsid antigen. This antigen is generally detectable in upper respiratory samples during the acute phase of infection. Positive results indicate the presence of viral antigens, but the clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out a bacterial infection or co-infection with other viruses.
The agent detected may not be the definite cause of the disease. Negative results from patients with symptom beyond seven days should be treated as presumptive and confirmed with a molecular assay, if necessary, for patient management. Negative results do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient’s recent exposures, history and the presence of clinical signs and symptoms consistent with COVID19.
The SARS-CoV-2 Antigen Rapid Test is intended for use by trained clinical laboratory personnel and individuals trained in point of care settings. SARS-CoV-2 Antigen Rapid Test is intended to be used as an aid in the diagnosis of SARS-CoV-2 infection.
The novel coronaviruses belong to the β genus.1 COVID-19 is an acute respiratory infectious disease. People are generally susceptible. Currently, the patients infected by the novel coronavirus are the main source of
infection; asymptomatic infected people can also be an infectious source. Based on the current epidemiological investigation, the incubation period is 1 to 14 days, mostly 3 to 7 days. The main manifestations include fever, fatigue and dry cough. Nasal congestion, runny nose, sore throat, myalgia and diarrhoea are found in a few cases.
The SARS-CoV-2 Antigen Rapid Test is a qualitative membrane-based chromatographic immunoassay for the qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 in human nasal swab
When specimens are processed and added to the test cassette, SARS-CoV-2 antigens, if present in the specimen, will react with the anti-SARS-CoV-2 antibody-coated particles, which have been pre-coated on the test strip. The mixture then migrates upward on the membrane by capillary action. The antigen-conjugate complexes migrate across the test strip to the reaction area and are captured by a line of antibody bound on the membrane. Test results are interpreted visually at 15-30 minutes based on the presence or absence of visually coloured lines.
To serve as a procedure control, a coloured line will always appear in the control line region, indicating that the proper volume of specimen has been added and membrane wicking has occurred.
The test cassette contains anti-SARS-CoV-2 antibodies. The positive control swab contains SARS-CoV-2 recombinant antigen pre-coated on the swab.
- For professional in vitro diagnostic use only. Do not use after the expiration date.
- Do not eat, drink, or smoke in the area where the specimens or kits are handled.
- Do not use the test if the pouch is damaged.
- Handle all specimens as if they contain infectious agents. Observe established precautions against biological hazards throughout testing and follow the standard procedures for proper disposal of specimens.
- Wear protective clothing such as laboratory coats, disposable gloves, mask and eye protection when specimens are being tested.
- The used test should be discarded according to local regulations. The used test should be considered potentially infectious and be discarded according to local regulations.
- Humidity and temperature can adversely affect results.
- This package insert must be read completely before performing the test. Failure to follow directions in insert may yield inaccurate test results.
- The test line for a high viral load sample may become visible within 15 minutes, or as soon as the sample passes the test line region.
- The test line for a low viral load sample may become visible within 30 minutes.
STORAGE AND STABILITY
- The kit can be stored at temperatures between 2 – 30 °C.
- The test is stable until the expiration date printed on the sealed pouch.
- The test must remain in the sealed pouch until use.
- DO NOT FREEZE.
- Do not use after the expiration date.
- Test Cassettes
- Extraction Tubes
- Positive Control Swab
- Negative Control Swab
- Disposable Swabs*
- Extraction Buffer
- Package Insert
* The Disposable Swabs are produced by another manufacturer.
Materials Required But Not Provided:
- Personal Protective Equipment
SPECIMEN COLLECTION AND PREPARATION
The SARS-CoV-2 Antigen Rapid Test can be performed using nasal swab specimens.
Testing should be performed immediately after specimen collection, or at most within one (1) hour after specimen collection, if stored at room temperature (15-30°C).
To collect a nasal swab sample:
- Carefully insert a Disposable Swab, provided with your kit, into one nostril. Using gentle rotation, push the swab up to 2.5 cm (1 inch) from the edge of the nostril.
- Rotate the swab 5 times against the mucosa inside the nostril to ensure sufficient specimen collection.
- Using the same swab, repeat this process in the other nostril to ensure that an adequate amount of sample is collected from both nasal cavities.
- Withdraw the swab from the nasal cavity. The specimen is now ready for preparation using the extraction buffer tubes.
DIRECTIONS FOR USE
Allow the test and extraction buffer to reach room temperature (15-30 °C) prior to testing.
- Use an extraction buffer tube for each specimen to be tested and label each tube appropriately.
- Hold the extraction buffer bottle upside down vertically, then add approximately 300 μL (10~12 drops) of extraction buffer to the extraction tube.
- Insert the swab into the tube and swirl it for 30 seconds. Then rotate the swab at least 5 times while squeezing the sides of the tube. Take care to avoid splashing contents out of the tube.
- Remove the swab while squeezing the sides of the tube to extract the liquid from the swab.
- Attach the dropper tip firmly onto the extraction buffer tube containing the sample. Mix thoroughly by swirling or flicking the bottom of the tube.
- Remove the test cassette from the foil pouch and use it as soon as possible.
- Place the test cassette on a flat and clean surface.
- Add the processed specimen to the sample well of the test cassette.
- Invert the extraction buffer tube with the dropper tip pointing downwards and hold it vertically.
- Gently squeeze the tube, dispensing 4 drops of the processed specimen into the sample well.
- Wait for the coloured line(s) to appear. The result should be read at 15-30 minutes. Do not read the result after 30 minutes.
INTERPRETATION OF RESULTS
(Please refer to the illustration above)
NEGATIVE: Only one coloured control line appears in the control region (C). No apparent coloured line appears in the test line region (T). This means that no SARS-CoV-2 antigen was detected.
POSITIVE:* Two distinct coloured lines appear. One line in the control line region (C) and the other line in the test line region (T). This means that the presence of SARS-CoV-2 antigen was detected.
*NOTE: The intensity of the colour in the test line (T) may vary depending on the level of the SARS-CoV-2 antigen present in the specimen. Therefore, any shade of colour in the test line region (T) should be considered positive.
INVALID: Control line fails to appear. Insufficient specimen volume or incorrect operation are the most likely reasons for control line failure. Review the procedure and repeat the test with a new test cassette. If the problem persists, discontinue using the test kit immediately and contact your local distributor.
Internal procedural controls are included in the test. A coloured line appearing in the control line region (C) is an internal procedural control. It confirms sufficient specimen volume and correct procedural technique.
Positive and Negative control swabs are supplied with each kit. These control swabs should be used to ensure that the test cassette and that the test procedure is performed correctly. Follow the “DIRECTIONS
FOR USE” section to perform the control test.
The control swabs can be tested under any of the following circumstances:
- When a new batch of tests are used and/or when a new operator performs the test.
- At periodic intervals as dictated by local requirements, and/or by the user’s Quality Control procedures.
- The SARS-CoV-2 Antigen Rapid Test is for in vitro diagnostic use only. The test should be used for the detection of SARS-CoV-2 antigens in nasal swab specimens only. The intensity of the test line does not necessarily correlate to SARS-CoV-2 viral titer in the specimen.
- Specimens should be tested as quickly as possible after specimen collection and at most within the hour following collection.
- The use of viral transport media may result in decreased test sensitivity.
- A false-negative test may result if the level of antigen in a sample is below the detection limit of the test or if the sample was collected incorrectly.
- Test results should be correlated with other clinical data available to the physician.
- A positive test result does not rule out co-infections with other pathogens.
- A positive test result does not differentiate between SARS-CoV and SARS-CoV-2.
- A negative test result is not intended to rule out other viral or bacterial infections.
- A negative result, from a patient with symptom onset beyond seven days, should be treated as presumptive and confirmed with a molecular assay, if necessary, for clinical management. (If the differentiation of specific SARS viruses and strains is needed, additional testing is required.)